Insider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Buys 50,000 Shares of Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 50,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $18.46 per share, for a total transaction of $923,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Accelerate Diagnostics, Inc. (AXDX) traded down $0.80 during mid-day trading on Monday, hitting $18.75. 442,000 shares of the company traded hands, compared to its average volume of 332,405. Accelerate Diagnostics, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $30.45.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Buys 50,000 Shares of Stock” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/13/insider-buying-accelerate-diagnostics-inc-axdx-director-buys-50000-shares-of-stock.html.

Several equities analysts have commented on the stock. ValuEngine downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub downgraded shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating and two have issued a buy rating to the company. Accelerate Diagnostics currently has a consensus rating of “Hold” and an average price target of $33.00.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc lifted its position in Accelerate Diagnostics by 0.3% during the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock worth $123,000 after purchasing an additional 15 shares during the period. CLS Investments LLC bought a new stake in Accelerate Diagnostics during the second quarter worth about $137,000. Quantbot Technologies LP bought a new stake in Accelerate Diagnostics during the second quarter worth about $228,000. UBS Asset Management Americas Inc. bought a new stake in Accelerate Diagnostics during the second quarter worth about $243,000. Finally, SG Americas Securities LLC lifted its position in Accelerate Diagnostics by 87.8% during the second quarter. SG Americas Securities LLC now owns 11,054 shares of the medical research company’s stock worth $302,000 after purchasing an additional 5,169 shares during the period. 44.44% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply